Core Viewpoint - Wall Street anticipates flat earnings for Kodiak Gas Services (KGS) in the upcoming quarter, with earnings expected to be $0.39 per share, unchanged from the previous year, while revenues are projected to increase by 51.4% to $326.16 million [1][3]. Earnings Expectations - The stock price may rise if the actual earnings exceed expectations in the earnings report scheduled for May 7, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that the Most Accurate Estimate for Kodiak Gas is lower than the consensus estimate, resulting in an Earnings ESP of -14.29%, indicating a bearish sentiment among analysts [10]. - The current Zacks Rank for Kodiak Gas is 3, which complicates the prediction of an earnings beat [11]. Historical Performance - In the last reported quarter, Kodiak Gas had an earnings surprise of +3.85%, reporting $0.27 per share against an expectation of $0.26 [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - Kodiak Gas does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, but investors should consider other factors before making investment decisions [16].

Coterra Energy Inc. (CTRA) is set to release first-quarter 2025 results on May 5. The Zacks Consensus Estimate for the to-be-reported quarter is a profit of 76 cents per share on revenues of $1.9 billion.Let’s delve into the factors that might have influenced the oil and gas exploration and production firm’s performance in the March quarter. But it’s worth taking a look at CTRA’s previous-quarter performance first.Highlights of CTRA's Q4 Earnings & Surprise HistoryIn the last reported quarter, the Houston, ...

Core Viewpoint - Exxon Mobil Corporation (XOM) is expected to report a decline in first-quarter 2025 earnings, with a consensus estimate of $1.72 per share, reflecting a 16.5% decrease from the previous year [1]. Earnings Expectations - The Zacks Consensus Estimate for first-quarter revenues is $84.5 billion, indicating a 1.7% increase from the year-ago figures [1]. - XOM has beaten earnings estimates in three of the last four quarters, with an average surprise of 1.8% [2]. - The company has a positive Earnings ESP of +1.62% and a Zacks Rank of 3 (Hold) [3]. Upstream Earnings and Market Conditions - XOM anticipates a sequential increase in upstream earnings for the March quarter by up to $800 million, attributed to favorable oil and gas prices [4]. - The average WTI spot prices for January, February, and March 2025 were $75.74, $71.53, and $68.24 per barrel, respectively, which are significantly above break-even prices in shale plays [4]. Energy Products Business - The Energy Products business unit is expected to see a sequential improvement of $300-$700 million due to changes in industry margins [5]. Stock Performance and Valuation - XOM's stock has decreased by 3.4% over the past year, outperforming the industry decline of 9.1% [8]. - The company's trailing 12-month EV/EBITDA ratio is 6.76, indicating it is trading at a premium compared to the industry average of 4.02 [10]. Strategic Developments - The acquisition of Pioneer Natural Resources enhances XOM's production capabilities in the Permian Basin, known for low production costs [12]. - XOM is investing in alternative energy projects, such as carbon capture and lithium battery technology, which present potential growth opportunities despite requiring substantial capital [14]. Competitor Analysis - Chevron (CVX) is also set to report first-quarter 2025 earnings on May 2, with an Earnings ESP of -5.51% [15]. - BP has reported first-quarter 2025 adjusted earnings of 53 cents per share, missing the consensus estimate and declining from the previous year's figure [16][17].

Core Viewpoint - United States Steel Corporation (X) is expected to report first-quarter 2025 results on May 1, with a consensus estimate indicating a revenue decline and potential challenges in earnings performance [1][3][12]. Revenue Estimates - The Zacks Consensus Estimate for first-quarter consolidated revenues is $3,621.6 million, reflecting a year-over-year decline of 12.9% [3]. Factors Influencing Performance - Operational efficiencies, cost management, and increased volumes from Big River Steel and Big River 2 (BR2) are anticipated to positively impact performance [4]. - However, weaker year-over-year prices and soft demand in Europe are likely to negatively affect results [4]. Price Trends - U.S. steel prices fell sharply last year, with benchmark hot-rolled coil (HRC) prices dropping over 40% from $1,200 per short ton to around $700 per short ton [5]. - Recent price hikes and tariffs have increased HRC prices to above $900 per short ton, but the benefits may not be fully realized in the first quarter [6]. Segment Performance - The Flat-Rolled segment is expected to perform well due to a strong commercial strategy, while the Mini Mill segment is projected to grow from higher volumes [9]. - Demand remains weak in Europe, and the Tubular segment faces challenges from a weak pricing environment [9]. Average Realized Prices - Estimated average realized prices for the Flat-Rolled unit is $960, an 8.9% year-over-year decrease; for the Mini Mill segment, it is $797, an 18.4% decrease; for the European segment, it is $760, an 8.5% decline; and for the Tubular unit, it is $1,643, a 27.5% decline [10]. Earnings Prediction - The earnings ESP for U.S. Steel is -2.79%, with a consensus estimate indicating a loss of 48 cents for the first quarter [12].

Core Viewpoint - Jazz Pharmaceuticals is expected to report first-quarter 2025 earnings on May 6, with sales estimated at $978.6 million and earnings at $4.61 per share, reflecting a positive trend in earnings estimates for 2025 [1][3]. Financial Performance - Jazz Pharmaceuticals has exceeded earnings expectations in three of the last four quarters, with a trailing four-quarter average earnings surprise of 3.20% and a notable earnings surprise of 13.99% in the last quarter [3]. - The company currently has an Earnings ESP of -2.75% and a Zacks Rank of 3 (Hold) [5]. Revenue Segments - The company reports financial figures under two segments: Neuroscience and Oncology. The consensus estimate for neuroscience product sales is $649 million, while the estimate for oncology sales is $269 million [7][10]. - Sales of the sleep disorder drug Xywav are projected at $372 million, with expectations of continued growth due to its uptake in narcolepsy and idiopathic hypersomnia [8]. - Epidiolex sales are expected to rise to $234 million, driven by geographic expansion, while sales of the legacy drug Xyrem are anticipated to decline [9]. Oncology Performance - Sales of the chemotherapy drug Rylaze are expected to be impacted by recent updates to treatment protocols, with estimates pegged at $103 million [11]. - Other oncology drugs, including Zepzelca, Vyxeos, and Defitelio, are expected to grow at a mid-single-digit percentage during the quarter [11]. Stock Performance and Valuation - Jazz Pharmaceuticals' shares have declined about 6% year-to-date, compared to a 4% decline in the industry, and are currently trading below their 50-day and 200-day moving averages [13]. - The stock is trading at a price-to-sales (P/S) ratio of 1.76, lower than the industry average of 1.97 and below its five-year mean of 2.70, indicating a valuation discount [16]. Investment Thesis - The company has a diversified portfolio in neuroscience and oncology, although pipeline setbacks, such as the discontinuation of suvecaltamide development, pose concerns [18]. - Strategic acquisitions have bolstered the pipeline, with five oncology products marketed and an FDA decision on a sixth product expected by August 18 [19][20]. - Despite challenges, the rising EPS estimates for 2025 and a robust cash reserve of $3.0 billion at the end of 2024 provide reasons to remain invested in Jazz Pharmaceuticals [21].

The Zacks Mining – Gold industry is housed within the broader Zacks Basic Materials sector. The Q1 earnings picture for this sector looks glum. Basic Materials is among the Zacks sectors that are expected to see the biggest decline in earnings in the first quarter. Overall earnings for the space are projected to fall 17.8% on 0.7% lower revenues, per the latest Earnings Preview. Gold mining companies’ first-quarter results are expected to reflect the benefits of higher gold prices and efforts to boost opera ...

Suncor Energy Inc. (SU) is set to report first-quarter 2025 earnings on May 6, after the closing bell. The Zacks Consensus Estimate for earnings is pegged at 86 cents per share and the same for revenues is pinned at $8.34 billion.Let us delve into the factors that might have influenced SU’s performance in the to-be-reported quarter. Before that, it is worth taking a look at the company’s performance in the last reported quarter.Highlights of SU’s Q4 Earnings & Surprise HistoryIn the previous reported quarte ...

Medical Properties Trust, Inc. (MPW) — also known as MPT — is scheduled to report first-quarter 2025 earnings results on May 1, before the opening bell. The company’s quarterly results are expected to reflect a year-over-year decline in revenues and normalized funds from operations (FFO) per share.In the last reported quarter, this real estate investment trust (REIT), which acquires and develops net-leased hospital facilities, posted a normalized FFO per share of 18 cents, beating the Zacks Consensus Estima ...

Martin Marietta Materials, Inc. (MLM) is scheduled to report first-quarter 2025 results on April 30, before market open.In the last reported quarter, the company reported mixed results, with earnings beating the Zacks Consensus Estimate by 4.1% but revenues missing the same by 1.3%. Both the top and bottom lines increased 1% and 3% on a year-over-year basis, respectively.Martin Marietta’s earnings topped the consensus mark in two of the last four quarters and missed on two occasions, with an average negativ ...

W.W. Grainger, Inc. (GWW) is scheduled to report first-quarter 2025 results on May 1, before the opening bell.The Zacks Consensus Estimate for GWW’s sales is pegged at $4.33 billion, indicating 2.4% growth from the year-ago reported figure.The consensus estimate for earnings is pegged at $9.46 per share. The consensus estimate for GWW’s earnings has moved down 0.2% in the past 60 days. The estimate indicates a year-over-year dip of 1.7%.  Image Source: Zacks Investment Research GWW’s Earnings Surprise Histo ...